---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-224022"
form_type: "8-K"
ticker: "RCEL"
cik: "0001762303"
company_name: "AVITA Medical, Inc."
filed_at: "2026-05-14T20:10:17+00:00"
generated_at: "2026-05-14T20:12:45.847356+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# AVITA Medical Q1 revenue $19.3M (+4% YoY); net loss narrows to $10.6M

## Summary
- Total revenue $19.3M, up 4% YoY and 10% sequentially, driven by Cohealyx and improved RECELL utilization.
- Net loss $10.6M ($0.35 loss per share) vs $13.9M ($0.53 loss) in Q1 2025; operating expenses down 11% to $24.5M.
- Gross profit margin 81.7% (vs 84.7%) due to product mix; RECELL-only margin 85.0%.
- Reaffirmed FY2026 revenue guidance $80-85M, representing growth of 12-19%.
- Appointed Cary Vance as President and CEO; Jan Stern Reed as independent Chair of the Board.

## SEC filing metadata
- accession: 0001193125-26-224022
- form_type: 8-K
- ticker: RCEL
- cik: 0001762303
- company_name: AVITA Medical, Inc.
- filed_at: 2026-05-14T20:10:17+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1762303/000119312526224022/0001193125-26-224022-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1762303/000119312526224022/rcel-20260514.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-224022
- JSON: https://secwatch.observer/filing/0001193125-26-224022.json
- Plain text: https://secwatch.observer/filing/0001193125-26-224022.txt

## Key facts
- Earnings Releases
  AVITA Medical, Inc. reported first quarter ended March 31, 2026 results: revenue approximately $19.3 million, net income $10.6 million, EPS $0.35 per basic and diluted share. Guidance reaffirmed.
  - Period: first quarter ended March 31, 2026
  - Revenue: approximately $19.3 million
  - Net income: $10.6 million
  - EPS: $0.35 per basic and diluted share
  - Guidance: reaffirmed
  - Result: reported results
  source text: today reported financial results for the first quarter ended March 31, 2026. First Quarter 2026 Financial Highlights and Recent Business Updates • Total revenue of approximately $19.3 million, up 4% year-over-year and approximately 10% sequentially, driven by contributions from Cohealyx ® and improved RECELL ® utilization as reimbursement dynamics normalize •
  evidence_url: https://www.sec.gov/Archives/edgar/data/1762303/000119312526224022/0001193125-26-224022-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.